Cambridge Healthtech Institute’s 4th Annual

Immunomodulatory Approaches

Harnessing the Immune Response and Overcoming Inhibitory Factors

18-19 March 2019

 

The Immunomodulatory Approaches conference track examines the multiple factors that interact in the tumour microenvironment including the cells involved and immunocytokines. Investigators are coming up with clever and often complex ideas for stimulating the immune response and targeting the immuno-stimulatory shield. There is a focus on T-cell effectors, myeloid-derived suppressor cells, Treg suppression, clever targeting, and innovations with antibody format regarding Fc engagement. Attendees will learn about the advances being made by the pioneers in this exciting field.

Preliminary Agenda

KEYNOTE

Targeting Regulatory T Cells in Cancer: Means and Mechanisms

Sergio A Quezada, PhD, Professor, University College London Cancer Institute

OVERCOMING LIMITATIONS OF CHECKPOINT INHIBITORS AND ANTAGONISTS

Targeting Tregs to Manipulate the Tumour Vasculature and Enhance T-Cell Tumour Targeting

Awen Gallimore, DPhil, Professor, Immunology, Infection and Immunity, Cardiff University

Targeting Myeloid-Derived Suppressor Cells to Overcome Resistance to Checkpoint Inhibitors

R.J. Tesi, MD, CEO and CMO, Inmune Bio

AGONISTS TOGETHER WITH T-CELL STIMULATION AND CHECKPOINT INHIBITORS

Tumor-Targeted 4-1BB Bispecific Antibody in Combination with T Cell Bispecific Antibody in Cancer Immunotherapy

Wei Xu, MD, PhD, Principal Scientist, Cancer Immunotherapy Discovery, Pharmaceutical Research and Early Development, Roche Innovation Center

Development of an ICOS/PD-L1 Bispecific

Matthew McCourt, PhD, Vice President, Immuno-Oncology, Kymab

Dual T Cell Costimulation and PD-1 Blockade via the Bispecific Antibody XmAb23104: Hitting the Accelerator and Releasing the Brakes on TILs

Michael Hedvat, PhD, Group Leader, Cell Biology, Xencor, Inc.

NEXT GENERATION BITES

Simultaneous Multiple Interaction T Cell Engaging (SMITE) Bispecifics: Silence and Synergy through T Cell Costimulation

Colin Correnti, PhD, Senior Scientist, Fred Hutchinson Cancer Research Center

Targeting Cancer with BiTE® Antibody Constructs

Roman Kischel, PhD, Director, Research, Amgen Research Munich

IMPORTANCE OF CYTOKINES

Next Generation Antibody-Cytokine Fusion Proteins

Dario Neri, PhD, Professor, Biomacromolecules, Chemistry and Applied Biosciences, ETH Zürich

Exploratory Studies up to IND with NKTR255, a Memory T-Cell Stimulating Cytokine

Jonathan Zalevsky, PhD, Senior Vice President, Biology and Clinical Development, Nektar Therapeutics

INNOVATIVE APPROACHES WITH CLINICAL BENEFITS

A Therapeutic Antibody Targeted Approach for Triple-Negative Breast Cancer

Sophia N. Karagiannis, BA, MS, PhD, Reader, Translational Cancer Immunology, St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King's College London

Key Clinical Learnings and Advancing the Pipeline of the ImmTAC TCR-Based Bi-Specific Biologic Platform

Joseph Dukes, PhD, Director & Head, Biology, Immunocore, Ltd.

FOCUS ON Fc ENGAGEMENT FOR EFFECTIVE TARGETING

The Sting in the Tail of Antibody Therapy

Stephen A. Beers, PhD, Professor of Immunology and Immunotherapy, Centre for Cancer Immunology, University of Southampton

Fc-Optimized Immuno-Modulatory Antibodies

Rony Dahan, PhD, Assistant Professor, The Rina Gudinski Career Development Chair, Cancer Immunology and Immunotherapy Lab, Weizmann Institute of Science

ATOR-1017 - A Tumor Directed Fcγ-Receptor Cross Linking Dependent 4-1BB Agonistic Antibody

Karin Enell Smith, PhD, Senior Scientist, Preclinical Development, Alligator Bioscience




For more details on the conference, please contact:
Nicole Lyscom, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: +44 7791 866489
Email: nlyscom@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com